Skip to main content
. 2021 Feb 12;11:3731. doi: 10.1038/s41598-021-82172-w

Figure 4.

Figure 4

90Y-DOTA-αGPC3 RIT decreases tumor burden—(a) Serum AFP measurements in untreated (n = 11), non-radiolabeled αGPC3-DOTA treated (n = 12) and 90Y-DOTA-αGPC3 treated (n = 12) mice and (b) GTV measurements by 89Zr-DFO-αGPC3 immuno-PET in untreated (n = 10 pre-RIT, n = 9 post-RIT), non-radiolabeled αGPC3-DOTA treated (n = 9 pre-RIT, n = 10 post-RIT) and 90Y-DOTA-αGPC3 RIT treated (n = 10 pre-RIT, n = 11 post-RIT) mice before (day 0) and 30 days after therapy. Bar represents mean. Normality of data assessed via Shapiro Statistical analysis by One. Kruskal–Wallis with Dunn’s multiple comparison test was performed for pairwise comparisons. * denotes p < 0.05.